NEOMED-LABS is a contract research organization (CRO) offering high-quality clinical immunology laboratory services. We serve pharmaceutical corporations, biotechnology companies, and healthcare / non-profit organizations with our extensive expertise in delivering quality readouts for the clinical development of vaccines and immunotherapies. Currently, we support clinical vaccine development programs of multinational pharma companies. Our staff consists of over 60 experienced, dedicated scientists and technical experts, and our projects are supported by an extensive network of key opinion leaders (KOLs) as scientific advisors and consultants. We conduct GCLP-compliant immunomonitoring activities to support Phase I to Phase IV vaccine clinical trials. Located in the Montreal area (Quebec, Canada), an important scientific hub in North America and host to four major universities and several biotechnology companies, we benefit from cutting-edge technology platforms, as well as state-of-the-art laboratories with BSL 2 and BSL 3 facilities.
Montreal-based innovative mucosal vaccine delivery company. Initiated Phase I clinical trial to study the safety and immunogenicity of a nasal proteasome influenza vaccine.
ID Biomedical, a mid-sized vaccine company based in Vancouver, completes the acquisition of Intellivax.
Acquisition of ID Biomedical by GSK and inauguration of the GSK Vaccines North America site in Laval. Development of expertise in all areas of the vaccine R&D processes, from discovery to clinical development.
Launch of the NEOMED Institute’s initiative with the support of AstraZeneca, Pfizer, and the Government of Quebec. Inauguration of the NEOMED Institute’s small molecules site in their state-of-the-art laboratories in Saint-Laurent (Montreal).
The NEOMED Institute is recognized as a new Centre of Excellence in Commercialization and Research (CECR) with support from the Government of Canada.
New pharma partnership with GSK. Creation of a new Centre of Excellence in Biologics and Vaccines and inauguration of NEOMED Institute’s Laval site.
Creation of NEOMED-LABS.
Launch of NEOMED-LABS as a contract research organization (CRO) providing high-quality and high-throughput clinical immunomonitoring services. GSK’s entire immunomonitoring team that performed clinical serology testing, including post-licensure activities, is transferred into the new CRO NEOMED-LABS.